Topical injection of osteoprotegerin prevents alveolar bone loss in rat experimental periodontitis
- Other Title
Search this article
Osteoprotegerin (OPG) is a decoy receptor for Receptor Activator of NF-кВ Ligand (RANKL) and blocks differentiation and activation of osteoclasts. Clinical trials of OPG administration have been successfully performed for bone-destructive diseases such as osteoporosis, bone metastatic cancer, and rheumatoid arthritis. In the case of periodontitis, systemic administration of OPG has been reported to be effective for decreasing alveolar bone loss in rat models of experimental periodontitis. In this study, we investigated the effect of topical OPG injection every other day in a rat model of experimental periodontitis, which was established by a ligature placement at the upper 2 ndmolar. Micro-CT analysis revealed that the distance from the cement-enamel junction to the alveolar bone crest (CEJ-ABC) was higher in the ligature group, and that the CEJ-ABC was significantly shorter in the ligature-OPG group than in the ligature-control group on days 5 and 14 after ligaturing. Analysis of tartrate-resistant acid phosphatase (TRAP) staining revealed that the number of TRAP-positive cells (osteoclasts) was significantly lower in the ligature-OPG group than in the ligature-control group, having decreased to one-third by day 5. These results demonstrate that topical injection of OPG could prevent alveolar bone loss in rat experimental periodontitis, suggesting that OPG may be useful for alveolar bone preservation in periodontitis. Nihon Shishubyo Gakkai Kaishi(J Jpn Soc Periodontol)54(2):167-174, 2012.
- Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology)
Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology) 54 (2), 167-174, 2012
JAPANESE SOCIETY OF PERIODONTOLOGY